Publikationen 2004
Originalarbeiten
- Behringer K, Josting A, Schiller P, Eich HT, Bredenfeld H, Diehl V, Engert A. Solid tumors in patients treated for Hodgkin’s disease: A report from the German Hodgkin Lymphoma Study Group. Ann Oncol 2004; 15 (7): 1079-1085.
- Bredenfeld H, Franklin J, Nogova L, Josting A, Fries S, Mailänder V, Oertel J, Diehl V, Engert A; German Hodgkin's Lymphoma Study Group. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2004; 22(12):2424-9
- Brosteanu O, Hasenclever D, Loeffler M, Diehl V; German Hodgkin's Lymphoma Study Group. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Ann Hematol. 2004; 83(3):176-82.
- Eich HT, Staar S, Gossmann A, Engert A, Franklin J, Krug B, Diehl V, Lackner K, Müller R-P. The HD 12 panel of the German Hodgkin Lymphoma Study Group (GHSG) – A quality assurance program based on a multidisciplinary panel reviewing all patients` imaging. Am J Clin Oncol 2004; 27 (3): 279-284.
- Eich HT, Staar S, Gossmann A, Hansemann K, Skripnitchenko R, Kocher M, Semrau R, Engert A, Josting A, Franklin J, Krug B, Diehl V, Müller R-P. Centralized radiation oncological review of cross-sectional imaging of Hodgkin’s disease leads to significant changes of the required involved field – results of a quality assurance program of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 2004; 58 (4): 1121-1127.
- Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R, Hermann R, Doelken G, Koch P, Oertel J, Roller S, Worst P, Bischof H, Glunz A, Greil R, von Kalle K, Schalk KP, Hasenclever D, Brosteanu O, Duehmke E, Georgii A, Engert A, Loeffler M, Diehl V, Mueller RP, Willich N, Fischer R, Hansmann ML, Stein H, Schober T, Koch B; German Hodgkin's Lymphoma Study Group. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol. 2004; 15(2):276-82. [ENDAUSWERTUNG HD6]
Übersichtsarbeiten
- Borchmann P, Schnell R, Schulz H, Engert A. Monoclonal antibody-based immunotherapy of Hodgkin's lymphoma. Curr Opin Investig Drugs. 2004; 5(12):1262-7.
- Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma--diagnosis and treatment. Lancet Oncol. 2004; 5(1):19-26.
- Diehl V. Chemotherapy or combined modality treatment: the optimal treatment for Hodgkin's disease. J Clin Oncol. 2004; 22(1):15-8.
- Josting A, Behringer K, Engert A, Diehl V. [Modern pharmacotherapy of Hodgkin disease].Internist (Berl). 2004; 45(1):93-101.
- Klimm B, Engert A, Diehl V; German Hodgkin Lymphoma Study Group. Axillary swelling and a reduced general condition in a middle-aged man. Nat Clin Pract Oncol. 2004; 1(1):51-4; quiz 1 p following 54.
- Klimm B, Engert A, Diehl V: Avoiding toxicity by reduction of radiotherapy volume size following chemotherapy in patients with early-stage unfavorable Hodgkin’s Lymphoma. Am J Oncol Rev 2004; 3(6):342-344.
- Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol. 2004 Jan;5(1):11-8.